Flora Growth Issues 2023 Revenue Guidance of $90 Million to $105 Million Reflecting Anticipated Year Over Year Growth Exceeding 100%

Rhea-AI Summary

Flora Growth Corp. (NASDAQ: FLGC) announced its revenue guidance for 2023, projecting US$90 million to US$105 million, reflecting over 100% expected growth from the previous year. This growth is attributed to organic expansion in its House of Brands and Commercial & Wholesale divisions, alongside international operations stemming from its acquisition of Franchise Global Health in Germany. The company recorded significant achievements in 2022, including successful cannabis exports to multiple countries and acquisitions to enhance its product offerings. Flora aims to meet its 2022 targets while positioning itself for further growth amidst industry challenges.

Positive

• Revenue guidance for 2023 projected at US$90 million to US$105 million, reflecting expected growth over 100%.
• Successful acquisition of Franchise Global Health, expanding operations into Germany.
• Completed acquisitions of JustCBD and other CBD brands, enhancing product offerings.
• Initiated commercial cannabis exports to new international markets including the US and Europe.

Negative

• None.

Flora will host a webcast discussing 2023 guidance and recapping 2022 milestones at 4:30 pm ET on January 30, 2023. Register and join here.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Flora Growth Corp. (NASDAQ: FLGC) (“Flora'' or the “Company”), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today revenue guidance of US$90 million to US$105 million for fiscal year 2023. Flora is also offering its shareholders and the general public a 2022 year-end recap of the global cultivator’s growth and expansion highlights.

Flora’s 2023 revenue guidance of $90 million to $105 million reflects expected organic growth in the House of Brands division and expansion of the Commercial & Wholesale division capabilities. This forecasted growth also incorporates Flora’s new German-based business as established through the acquisition of Franchise Global Health. Flora’s German operations solidify a crucial foothold in a growing international cannabis market, providing a unique opportunity for operational synergies and diversified growth. Revenue growth is also expected to reflect the continued successful execution of product development and pricing strategies.

It is expected that the House of Brands and Commercial & Wholesale divisions will have roughly equal contributions to the top line, while the Pharmaceutical division is expected to contribute up to 10% of total revenue.

“We are pleased to announce that we will meet our guidance for 2022 and are issuing revenue guidance of $90 million - $105 million for the year 2023,” said Luis Merchan, Chairman and CEO of Flora. “Our 2023 forecasted revenue range represents anticipated growth in excess of 100% over last year and highlights our continued momentum, despite a challenging macroeconomic backdrop that has disproportionately impacted the cannabis industry.”

Operating Highlights for 2022 Included:

• Acquired Franchise Global Health (FGH), an international cannabis company with primary operations in Germany.
• Raised gross proceeds of $5 million through a registered direct offering, further bolstering Flora’s liquidity position.
• Initiated commercial cannabis exports to new international markets including the United States, Switzerland and the Czech Republic.
• Completed acquisition of category-leading wellness brand JustCBD; expanding U.S. infrastructure and CPG portfolio.
• Completed construction of Bogota, Colombia-based Flora Lab 4, a laboratory specializing in prescription cannabis formulations.
• Flora appointed former Amazon executive Tim Leslie and former JP Morgan executive Brandon Konigsberg to its Board of Directors, named CEO Luis Merchan as Chairman of the Board of Directors, appointed former Amazon executive Elshad Garayev as Chief Financial Officer, and hired cannabis regulatory veteran Holly Bell as Vice President of Regulatory Affairs.
• As a result of the FGH acquisition, Flora appointed former FGH CEO Clifford Starke as President of Flora and Member of the Board of Directors and former FGH Chief Operating Officer Edward Woo as a member of the Board of Directors.
• Flora established JustCBD’s on-the-ground presence in the United Kingdom and distribution operations in the EU, opening offices in London.
• Flora acquired CBD brands Masaya and No Cap Hemp Co., enhancing new product offerings and revenue streams.
• Flora was awarded Best M&A Deal at the Benzinga Cannabis Capital Conference for the acquisition of JustCBD.

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands, designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. Visit www.floragrowth.com or follow @floragrowthcorp on social media for more information.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains ‘‘forward-looking statements,’’ as defined by federal securities laws. Forward-looking statements reflect Flora’s current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “plan,” “estimate,” “intend,” “predict,” “potential,” “continue,” and the negatives of these words and other similar expressions generally identify forward looking statements. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled “Risk Factors” in Flora’s Annual Report on Form 20-F filed with the SEC on May 9, 2022, as such factors may be updated from time to time in Flora’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora’s filings with the SEC. While forward-looking statements reflect Flora’s good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Flora (or to third parties making the forward-looking statements).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005219/en/

Investor Relations:

Sean Mansouri, CFA

ir@floragrowth.com

Public Relations:

Cassandra Dowell

+1 (858) 221-8001

flora@cmwmedia.com

Source: Flora Growth Corp.

FAQ

What is Flora Growth Corp.'s revenue guidance for 2023?

Flora Growth Corp. has projected its revenue guidance for 2023 between US$90 million and US$105 million.

What were Flora Growth Corp.'s key milestones in 2022?

Key milestones included the acquisition of Franchise Global Health, exports to new markets, and completion of significant brand acquisitions.

How does Flora Growth Corp. plan to achieve its growth forecasts?

The company's growth forecasts are based on organic growth in its House of Brands and Commercial & Wholesale divisions, alongside international expansion.

Which division is expected to contribute to Flora Growth Corp.'s 2023 revenue?

The House of Brands and Commercial & Wholesale divisions are expected to contribute roughly equally to the top line, with the Pharmaceutical division contributing up to 10%.